The 1-year cumulative incidences for primary and secondary outcomes were as follows: 0.99% vs. 1.64% for all-cause death; 0.32% vs. 0.20% for acute pancreatitis; 0.08% vs. 0.05% for chronic pancreatitis; and 0.08% vs. 0.06% for pancreatic cancer in GLP-1 RA Users and Non–GLP-1 RA Users, respectively (Fig. 1, Panels A and B). Here, GLP1R is linked to pancreatic neoplasm.